| Primary information |
|---|
| CancerPDF_ID | CancerPDF_ID1043 |
| PMID | 16395409 |
| Peptide Sequence | THRIHWESASLL |
| Peptide Sequence in Publication | THRIHWESASLL |
| Protein Name | Complement C3f |
| UniprotKB Entry Name | CO3_HUMAN |
| Biofluid | Serum |
| M/Z | 1449.76 |
| Charge | 1 |
| Mass/H+ | NA |
| Mass (in Daltons) | NA |
| Profiling Technique | MALDI-TOF |
| Peptide Identification Technique | Q/TOF/TOF and LC-MS/MS |
| Quantification Technique | NA |
| Labeling | Label Free |
| FDR | less than 1 Ã 10–5 |
| p-Value | 1.98E-14 |
| Software | MASCOT (v 2.0.04 for Windows) |
| Length of Peptide | 12 |
| Cancer Type | "Advanced Prostate, Breast and Bladder cancer" |
| Database for Peptide search | NCBI refseq Protein Database |
| Modification | NA |
| Number of Patients | "Advanced prostate (n = 32), breast (n = 21), and bladder (n = 20) cancer, 33 healthy" |
| Regulation/Differential Expression | "For Prostate & bladder (Higher) Differential ion intensity in cancer compare to normal with Ratio of median intensity (patients/Controls) =1885, 2646 and 437 in prostate, bladder and breast cancer respectively" |
| Validation | Independent validation |
| Sensitivity | 97.5% for multiclass and 100 % for binary classification system on independent validation dataset |
| Specificity | NA |
| Accuracy | 97.5 % on validation dataset |
| Secondary information |
|---|
| Peptide Atlas | NA |
| IEDB | 533899
|